Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Repaglinide

J A Balfour1, D Faulds

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs & Aging
|September 18, 1998
PubMed
Summary
This summary is machine-generated.

Repaglinide, a new insulin secretagogue, effectively manages type 2 diabetes by lowering blood glucose. It offers flexible dosing and a reduced risk of hypoglycemia compared to glibenclamide, even if meals are skipped.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Levetiracetam.

CNS drugs·2013
Same author

Becaplermin.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Combination hepatitis a-hepatitis B vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Oprelvekin: a review of its pharmacology and therapeutic potential in chemotherapy-induced thrombocytopenia.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Topical eflornithine.

American journal of clinical dermatology·2001
Same author

Telithromycin.

Drugs·2001
Same journal

Leveraging Real-World Data for Clinical Decision Making in Geriatric Oncology.

Drugs & aging·2026
Same journal

Drug Utilisation of Fall-Risk-Increasing Drugs (FRIDs) and Risk of Hospitalisation: A Nested Case-Control Study Among Community-Dwelling Older Adults.

Drugs & aging·2026
Same journal

Gabapentinoid Use and Risk of Alzheimer's Disease-Related Dementias: A Systematic Review and Meta-analysis of Observational Studies.

Drugs & aging·2026
Same journal

Development and Validation of Prescribing Appropriateness Criteria (PAC) for Sri Lankan Older Adults.

Drugs & aging·2026
Same journal

Adapting the Geriatric Medicine 5Ms Framework to Geriatric Dermatology.

Drugs & aging·2026
Same journal

External Validation of a Community Pharmacy-Based Screening Tool for Frailty That Uses Routinely Collected Data.

Drugs & aging·2026
See all related articles

Area of Science:

  • Pharmacology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Type 2 diabetes mellitus (T2DM) is a growing global health concern requiring effective management strategies.
  • Insulin secretagogues play a crucial role in T2DM treatment by stimulating insulin release.
  • Repaglinide represents a novel class of insulin secretagogues with a distinct mechanism of action.

Purpose of the Study:

  • To evaluate the efficacy and safety of repaglinide for managing type 2 diabetes mellitus.
  • To compare repaglinide's glycemic control with existing treatments like glibenclamide.
  • To assess the impact of repaglinide on fasting and postprandial blood glucose levels.

Main Methods:

  • Clinical trials involving patients with type 2 diabetes mellitus.

Related Experiment Videos

  • Comparative studies assessing glycemic control against glibenclamide.
  • Evaluation of repaglinide's pharmacokinetic profile (absorption, elimination, excretion).

    • Main Results:

    • Repaglinide effectively lowers fasting and postprandial blood glucose in diverse populations.
    • Repaglinide demonstrated comparable glycemic control to glibenclamide at various dosages.
    • Combination therapy with metformin and repaglinide improved glycemic control.
    • Repaglinide use was associated with a lower risk of hypoglycemia when meals were missed.

    Conclusions:

    • Repaglinide is an effective insulin secretagogue for type 2 diabetes management.
    • Its rapid absorption and elimination profile offer therapeutic flexibility.
    • Repaglinide provides a valuable treatment option, particularly for patients requiring flexible meal scheduling.